What drove the recent RVV.CN stock surge?

The rise reflected heavy volume of **2,312,244** shares and speculative interest ahead of an earnings announcement on **26 Feb 2026** plus attention on clinical programs. Near-term clinical updates and funding signals likely drove the move.

Is RVV.CN stock a buy after the 50% jump?

RVV.CN stock remains speculative. Meyka AI gives a Grade B (HOLD). With EPS **-0.03** and low liquidity, buyers should wait for clinical data or clearer funding before long-term allocation.

What price targets exist for RVV.CN stock?

Meyka AI's model projects a quarterly target **C$0.03** (≈100% upside) and a monthly point **C$0.01** (≈-33% downside). These are model projections, not guarantees.

How risky is trading RVV.CN stock?

High risk: development-stage fundamentals, negative PE, low current ratio **0.03**, and possible dilution. Volume spikes can create fast moves; use tight risk limits and size positions accordingly.

CA Stocks

RVV.CN Revive Therapeutics up 50% to C$0.015 on CNQ 18 Feb 2026: catalyst eyed

ByHuzaifa Zahoor February 18, 2026February 18, 2026

RVV.CN stock led Canadian small-cap gainers on 18 Feb 2026, rising 50.00% to C$0.015 on the CNQ exchange in Canada. Trading volume hit 2,312,244 shares versus an average of 310,509, a 7.45x surge that supports the move. The jump comes ahead of an earnings announcement on 26 Feb 2026 and after recent clinical-stage program updates for Bucillamine and psilocybin programs, which traders are watching closely.